Full Press Release Details
Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
Calif., November 13, 2023 - LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq:
LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy
benefit, today provided an update on its progress.
Trial and Other Advancements
LIXTE has made advances in the development of LB-100 through important collaborations, including the following:
| Collaboration with GSK and The University of Texas - MD Anderson Cancer Center in an investigator-initiated Phase 1b/2 clinical trial assessing whether adding LB-100 to GSK's programmed death receptor-1 (PD-1)-blocking monoclonal antibody may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma. GSK will provide dostarlimab and financial support for the clinical trial. In addition to MD Anderson, the trial also will be open at Northwestern University's Robert H. Lurie Comprehensive Cancer Center. | |
| The first patient was enrolled in the Spanish Sarcoma Group (Grupo Espa ol de Investigaci n en Sarcomas - GEIS) trial to determine whether LB-100 given with a standard dose of doxorubicin for the treatment of advanced soft tissue sarcomas (ASTS) will improve progression-free survival and overall survival. This trial will enroll up to 170 patients and will begin in partnership with GEIS clinical sites. | |
| Sarah Cannon Research Institute (SCRI) joined the City of Hope 's ongoing Phase 1b clinical trial evaluating the addition of LB-100 to chemotherapy and immunotherapy for previously untreated, extensive-stage small cell lung cancer. Adding SCRI is expected to reduce the time required to demonstrate the feasibility, tolerability and efficacy of adding LB-100 to the current standard of care. | |
| Expanded collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study pre-clinical drug synergies of LB-100 with chemotherapy and immunotherapy in various cancers. The expansion follows a successful two-year collaboration in colon cancer and seeks to discover additional treatment combinations with LB-100 for other cancer types. A recently posted article in BioRxiv detailed that the collaboration demonstrated that inhibition of PP2A in colon cancer cells by LB-100 may lead to an improvement in immunotherapy response. |
van der Baan, LIXTE's recently-appointed President and Chief Executive Officer, said, "Since the beginning of this year,
LIXTE has been expanding its collaborations with several prestigious, world-renowned cancer research institutions and pharmaceutical
companies that are testing our LB-100 compound to improve chemotherapy and immunotherapy treatment outcomes. We believe that LB-100 may
offer broad applicability to many types and stages of cancer, with the potential to benefit a wide range of patients."
of September 30, 2023 Quarterly Report on Form 10-Q
information with respect to LIXTE's business, clinical trials and financial condition is contained in the Company's Quarterly
Report on Form 10-Q for the quarterly period ended September 30, 2023, which has been filed with the U.S. Securities and Exchange Commission
LIXTE Biotechnology Holdings, Inc.
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy, PP2A inhibitors. The
Company's novel approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment
options for patients. At the core of the Company's therapy is LB-100, LIXTE's proprietary molecule that acts as
an inhibitor of the PP2A phosphatase with a favorable toxicity profile. LB-100 promotes the production of neoantigens
and cytokines, boosts T-cell proliferation, and disrupts the DNA repair mechanisms of cancer cells, potentially improving treatment outcomes.
The Company is conducting multiple clinical trials for solid tumors with unmet medical needs. LIXTE's unique approach has
no known competitors and is covered by a comprehensive patent portfolio.
information about LIXTE can be found at www.lixte.com, on LinkedIn at https://www.linkedin.com/company/lixte-biotechnology-holdings-inc-/,
on Twitter at https://twitter.com/LixteBiotech, and by reviewing the Company's filings with the United States Securities
and Exchange Commission at https://www.sec.gov.
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's clinical trials and collaborators
in such clinical trials, business strategy and other plans and objectives for future operations, and assumptions and predictions about
future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results
of clinical trials, and the patent and legal costs to protect and maintain the Company's intellectual property worldwide, are all
forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate,"
"believe," "estimate," "potential(ly)," "continue," "forecast," "predict,"
"plan," "may," "will," "could," "would," "should," "expect"
or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected
in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide
assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the
Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research
results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction
with the Company's filings with the United States Securities and Exchange Commission at www.sec.gov.
more information about LIXTE, Contact:
Phone: (631) 830-7092
Investor Phone: (888) 289-5533
PondelWilkinson Inc. Investor
Roger Pondel or Laurie Berman: (310) 279-5980